A Study of Two Forms of Pentamidine in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS - Full Text View

Purpose

To compare parenteral versus inhaled pentamidine in patients with documented Pneumocystis carinii pneumonia (PCP) with AIDS.

Condition	Intervention
Pneumonia, Pneumocystis Carinii HIV Infections	Drug: Pentamidine isethionate

MedlinePlus related topics:

AIDS Pneumonia

Drug Information available for:

Pentamidine

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized

Official Title:	Inhaled Versus Intravenous Pentamidine in Pneumocystis Carinii Pneumonia in the Acquired Immunodeficiency Syndrome

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Exclusion Criteria

Co-existing Condition:

Patients with the following are excluded:

Previous history of adverse reaction to pentamidine.
History of asthma.
Pulmonary Kaposi's sarcoma.

Patients with the following are excluded:

Previous history of adverse reaction to pentamidine.
History of asthma.
Pulmonary Kaposi's sarcoma.
Inability to understand the consent procedure.

All patients hospitalized at Cedars-Sinai Medical Center with AIDS and possible Pneumocystis carinii pneumonia (PCP) will be eligible.

Patients with HIV antibody or AIDS and a clinical presentation suggesting PCP are eligible.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00002292

Locations


United States, Illinois
	LyphoMed Inc
	Rosemont, Illinois, United States, 60018

Sponsors and Collaborators

LyphoMed

More Information

Publications:

Soo Hoo GW, Mohsenifar Z, Meyer RD. Inhaled or intravenous pentamidine therapy for Pneumocystis carinii pneumonia in AIDS. A randomized trial. Ann Intern Med. 1990 Aug 1;113(3):195-202.

Conte JE Jr, Chernoff D, Feigal DW Jr, Joseph P, McDonald C, Golden JA. Intravenous or inhaled pentamidine for treating Pneumocystis carinii pneumonia in AIDS. A randomized trial. Ann Intern Med. 1990 Aug 1;113(3):203-9.

Study ID Numbers:	023B, 88-001
First Received:	November 2, 1999
Last Updated:	June 23, 2005
ClinicalTrials.gov Identifier:	NCT00002292
Health Authority:	United States: Food and Drug Administration

Keywords provided by NIH AIDS Clinical Trials Information Service:

AIDS-Related Opportunistic Infections

Pneumonia, Pneumocystis carinii

Pentamidine

Injections, Intravenous

Administration, Inhalation

Aerosols

Acquired Immunodeficiency Syndrome

Study placed in the following topic categories:

Opportunistic Infections

Sexually Transmitted Diseases, Viral

Clotrimazole

Pneumocystosis

Miconazole

Acquired Immunodeficiency Syndrome

Tioconazole

Immunologic Deficiency Syndromes

Virus Diseases

Mycoses

Pneumonia, Pneumocystis

Pneumocystis Infections

Respiratory Tract Infections

Respiratory Tract Diseases

HIV Infections

Lung Diseases

AIDS-Related Opportunistic Infections

Sexually Transmitted Diseases

Pentamidine

Retroviridae Infections

Pneumonia

Lung Diseases, Fungal

Additional relevant MeSH terms:

Trypanocidal Agents

Anti-Infective Agents

Antiparasitic Agents

Antiprotozoal Agents

RNA Virus Infections

Slow Virus Diseases

Immune System Diseases

Therapeutic Uses

Antifungal Agents

Lentivirus Infections

Infection

Pharmacologic Actions

ClinicalTrials.gov processed this record on December 03, 2008

Sponsored by:	LyphoMed
Information provided by:	NIH AIDS Clinical Trials Information Service
ClinicalTrials.gov Identifier:	NCT00002292